NICE TAs

28/04/2020

TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer

28/04/2020

TA546: Padeliporfin for untreated localised prostate cancer

28/04/2020

TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer

28/04/2020

TA565: Benralizumab for treating severe eosinophilic asthma

28/04/2020

TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs

28/04/2020

TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma

28/04/2020

TA585: Ocrelizumab for treating primary progressive multiple sclerosis

28/04/2020

TA542: Cabozantinib for untreated advanced renal cell carcinoma

28/04/2020

TA523: Midostaurin for untreated acute myeloid leukaemia

28/04/2020

TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia

28/04/2020

TA623: Patiromer for treating hyperkalaemia

28/04/2020

TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia

23/04/2020

TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes

23/04/2020

TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer

23/04/2020

TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs

23/04/2020

TA547: Tofacitinib for moderately to severely active ulcerative colitis

23/04/2020

TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma

23/04/2020

TA621: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer

23/04/2020

TA522: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia

23/04/2020

TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years